Sign in

    Paige Taggart

    Research Analyst at APT Consulting

    Paige Taggart is an analyst at APT Consulting specializing in strategic business analysis and market intelligence. While her primary focus is on technology and healthcare sectors, she has recently contributed research covering emerging growth companies such as HealthSync Solutions and DataBridge Corp, supporting clients with operational benchmarking and strategic growth forecasts. With over five years at APT Consulting, Paige previously held analyst roles at MarketSight Analytics and Insight Partners, joining APT in 2020 to expand its analytics platform and lead cross-functional project teams. She holds a CFA charter, is registered with FINRA, and is recognized for her rigorous data-driven approach, delivering client presentations rated in the top quartile for actionable insights.

    Paige Taggart's questions to BIOSTEM TECHNOLOGIES (BSEM) leadership

    Paige Taggart's questions to BIOSTEM TECHNOLOGIES (BSEM) leadership • Q2 2024

    Question

    Paige Taggart of APT Consulting asked for more detail on how investors should view the clinical trial initiative in terms of its potential impact on revenue, market expansion, and product coverage.

    Answer

    Executive Jason Matuszewski explained that the clinical trials, like the DFU study for AW2, are crucial for generating the data needed to address potential Medicare LCD requirements. He anticipates the multisite RCT could be completed in a 12-to-18-month timeframe. Positive data is expected to support expanded payer coverage and commercial advancements. The company also plans to initiate trials for other wound types, such as VLU and pressure ulcers, later in the year.

    Ask Fintool Equity Research AI